EGFR overexpression

News alerts, weekly reports and conference planners

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	necitumumab Sensitive: C2 – Inclusion Criteria necitumumab Sensitive : C2	necitumumab Sensitive: C2 – Inclusion Criteria necitumumab Sensitive : C2
EGFR overexpression	Squamous Cell Carcinoma of Head and Neck	EGFR overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: C2 – Inclusion Criteria cetuximab Sensitive : C2	cetuximab Sensitive: C2 – Inclusion Criteria cetuximab Sensitive : C2
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2
EGFR overexpression	Gastric Cancer	EGFR overexpression	Gastric Cancer	ASLAN001 Sensitive: C3 – Early Trials ASLAN001 Sensitive : C3	ASLAN001 Sensitive: C3 – Early Trials ASLAN001 Sensitive : C3
EGFR overexpression	Colorectal Cancer	EGFR overexpression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3
EGFR overexpression	Gastric Cancer	EGFR overexpression	Gastric Cancer	GC-1118A Sensitive: C3 – Early Trials GC-1118A Sensitive : C3	GC-1118A Sensitive: C3 – Early Trials GC-1118A Sensitive : C3
EGFR overexpression	Lung Adenocarcinoma	EGFR overexpression	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR overexpression	Colorectal Cancer	EGFR overexpression	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR overexpression	Hepatocellular Cancer	EGFR overexpression	Hepatocellular Cancer	gefitinib + lenvatinib Sensitive: C3 – Early Trials gefitinib + lenvatinib Sensitive : C3	gefitinib + lenvatinib Sensitive: C3 – Early Trials gefitinib + lenvatinib Sensitive : C3
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
EGFR overexpression	Thyroid Gland Papillary Carcinoma	EGFR overexpression	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
EGFR overexpression	Osteosarcoma	EGFR overexpression	Osteosarcoma	gemcitabine Resistant: D – Preclinical gemcitabine Resistant : D	gemcitabine Resistant: D – Preclinical gemcitabine Resistant : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABT-414 Sensitive: D – Preclinical ABT 263 + ABT-414 Sensitive : D	ABT 263 + ABT-414 Sensitive: D – Preclinical ABT 263 + ABT-414 Sensitive : D
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ONC201 Resistant: D – Preclinical ONC201 Resistant : D	ONC201 Resistant: D – Preclinical ONC201 Resistant : D
EGFR overexpression	Lung Cancer	EGFR overexpression	Lung Cancer	cetuximab + avelumab Sensitive: D – Preclinical cetuximab + avelumab Sensitive : D	cetuximab + avelumab Sensitive: D – Preclinical cetuximab + avelumab Sensitive : D
EGFR overexpression	Gastric Cancer	EGFR overexpression	Gastric Cancer	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D
EGFR overexpression	Breast Cancer	EGFR overexpression	Breast Cancer	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	nimotuzumab Sensitive: D – Preclinical nimotuzumab Sensitive : D	nimotuzumab Sensitive: D – Preclinical nimotuzumab Sensitive : D
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	afatinib + enzalutamide capsule Sensitive: D – Preclinical afatinib + enzalutamide capsule Sensitive : D	afatinib + enzalutamide capsule Sensitive: D – Preclinical afatinib + enzalutamide capsule Sensitive : D
EGFR overexpression	Estrogen Receptor Positive Breast Cancer	EGFR overexpression	Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: D – Preclinical palbociclib Resistant : D	palbociclib Resistant: D – Preclinical palbociclib Resistant : D
EGFR overexpression	Solid Tumor	EGFR overexpression	Solid Tumor	BB-1705 Sensitive: D – Preclinical BB-1705 Sensitive : D	BB-1705 Sensitive: D – Preclinical BB-1705 Sensitive : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR overexpression	Breast Cancer	EGFR overexpression	Breast Cancer	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D	LR004-VC-MMAE Sensitive: D – Preclinical LR004-VC-MMAE Sensitive : D
EGFR overexpression	Pancreatic Cancer	EGFR overexpression	Pancreatic Cancer	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D	HTI-1511 Sensitive: D – Preclinical HTI-1511 Sensitive : D

EGFR overexpression

Associations